P2Y12 inhibition after thrombotic thrombocytopenic purpura remission ( Author`s Reply )

Kaynakça (4)

1. Doğan A, Özdemir B, Bal H, Özdemir E, Kurtoğlu N. Ticagrelor-associated thrombotic thrombocytopenic purpura. Anatol J Cardiol 2017; 17: 73-4.
2. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082-115.
3. Loh JP, Torguson R, Pendyala LK, Omar A, Chen F, Satler LF, et al. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and secondgeneration drug-eluting stents. Am J Cardiol 2014; 113: 1968-76.
4. Patel TN, Kreindel M, Lincoff AM. Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report. J Invasive Cardiol 2006; 18: E211–3. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38: 845-53.